Dr. Rugo has led key breast most cancers remedy trials and exudes a ardour for serving sufferers.
Metropolis of Hope®, one of many largest and most superior most cancers analysis and therapy organizations in the US, whose Los Angeles complete most cancers heart is ranked among the many nation’s prime 5 most cancers facilities by U.S. Information & World Report, right now introduced that famend most cancers physician Hope S. Rugo, M.D., has joined Metropolis of Hope to guide its Ladies’s Cancers Program all through the group and breast medical oncology division part.
Dr. Rugo serves as Metropolis of Hope’s director, Ladies’s Cancers Program, and new division chief, Breast Medical Oncology, and professor within the Division of Medical Oncology & Therapeutics Analysis.
On this position, she is going to lead and improve Metropolis of Hope’s ladies’s cancers analysis and medical care throughout the enterprise, develop medical trials and translational analysis, and standardize most cancers care to attain superior affected person outcomes and experiences.
“It’s laborious to think about anybody within the breast most cancers subject who has not heard of Dr. Rugo’s extraordinary experience, deep compassion and dedication to bettering sufferers’ lives,” stated Marcel van den Brink, M.D., Ph.D., president, Metropolis of Hope Los Angeles and Metropolis of Hope Nationwide Medical Middle, and Deana and Steve Campbell Chief Doctor Govt Distinguished Chair in Honor of Alexandra Levine, M.D. “Dr. Rugo is a distinguished oncologist and visionary chief in medical trial design and execution, integrating focused therapies with normal therapies to reinforce take care of each early- and late-stage breast most cancers.”
She has contributed to research that led to new breast most cancers therapies, serving on the steering committees for a number of medical trials resulting in approval for PARP inhibitors, CDK4/6 inhibitors, PI3K inhibitors, checkpoint inhibitors and antibody drug conjugates, amongst others.
Moreover, Dr. Rugo has led a number of research geared toward minimizing therapy-related toxicity, resulting in the U.S. Meals and Drug Administration’s approval of scalp cooling caps to stop chemotherapy-induced hair loss and a steroid mouthwash to alleviate focused agent stomatitis, a aspect impact that may happen on account of some most cancers therapies.
As co-chair of the Triple Adverse Working Group of the Translational Breast Most cancers Analysis Consortium, Dr. Rugo has spearheaded and collaborated on groundbreaking, multicenter medical translational analysis trials. She served on management roles with the Breast Committee for the Alliance and directed a Section 3 trial, involving three pharmaceutical firms.
Dr. Rugo can also be an investigator and chair of the Security Committee for the multicenter adaptively randomized Section 2 I-SPY2 trial, which is designed to enhance outcomes in high-risk breast most cancers sufferers by testing new therapies that sufferers obtain earlier than their major therapy, comparable to surgical procedure. She additionally contributes her experience to the Novel Brokers Committee, additional advancing the sphere of breast most cancers analysis.
Dr. Rugo’s editorial work with American Society of Medical Oncology’s Schooling Committee and her co-chairing of latest tips for the hormonal therapy of metastatic breast most cancers show her dedication to shaping medical follow. Her service with the Superior and Early Breast Most cancers Tips Consensus Panel by the European Society of Medical Oncology and European Society of Oncology underscores her affect on a worldwide scale.
Dr. Rugo was beforehand on the College of California San Francisco for 35 years, the place she served in numerous medical and educational management roles.
Past her analysis, Dr. Rugo is a devoted clinician and educator, targeted on offering compassionate care to her sufferers. She shares her experience on breast most cancers therapy and supportive care at native, nationwide and worldwide conferences. She has printed or contributed to greater than 500 peer-reviewed journal articles and written greater than 100 journal views, editorials and e book chapters.
Constructing on its repute as a premier breast most cancers program, Metropolis of Hope is poised for continued progress and excellence below the management of Dr. Rugo. Her decades-long experience and affect within the subject might be instrumental in attracting top-tier physicians, nurses and employees, additional strengthening the establishment’s influence on affected person care and advancing breakthrough therapies.
A graduate of the College of Pennsylvania Faculty of Drugs, Dr. Rugo accomplished her residency in inner medication and first care, adopted by a fellowship in hematology and oncology on the College of California San Francisco. Her postdoctoral fellowship in immunology at Stanford College additional enriched her experience.
She has been celebrated for her excellence in affected person care, medical schooling and medical analysis, incomes quite a few nationwide and worldwide accolades, together with the Giants of Oncology in Breast Most cancers and Schooling and the European Society for Medical Oncology’s 2024 ESMO Breast Most cancers Award.
